Study Information
Status: Active, Not Recruiting
Study Details
View study details on clinicaltrials.gov.
Locations
San Francisco, Palo Alto/Santa Cruz, Greater Sacramento Valley
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment
Location: CPMC (San Francisco), SIMR (Sacramento) and PAMF (Peninsula/South Bay/Santa Cruz)
Please contact: ClinicalResearch@sutterhealth.org about study HARMONi Study (AK112-301)
Principal Investigator
Related Studies
The Impact of Smoking, Comorbidities, and Race/Ethnicity on COVID-19 Infection and Disease Severity
Using EHR from a large healthcare system in Northern CA, we will study the impact of smoking, comorbidities, race on COVID-19 infection and disease severity.
Investigator: Jiang Li, Ph.D., MPH